Skip to NavigationSkip to content

Novavax

Novavax and Janssen commit 90 million COVID-19 vaccine doses to UK Government with two new deals

The UK Government has signed a new deal with Johnson & Johnson and Novavax to secure 90 million orders of their vaccine candidates to protect against COVID-19 infection.  

One of the announced deals was to reserve 30 million doses of Ad26.COV2.S, the COVID-19 vaccine candidate developed by Janssen, the pharmaceutical subsidiary of J&J, for not-for-profit emergency pandemic use. As part of the deal, the UK Government has the option to purchase a further 22 million doses of the vaccine if required.

Novavax inks deal to deliver one billion COVID-19 vaccine doses in India and other regions

Novavax is partnering up with the Serum Institute of India Private Limited (SIIPL) in a licensing deal to development and marketing of up to one billion doses of its potential recombinant COVID-19 vaccine candidate, NVX‑CoV2373.

The new deal covers the clinical development, co-formulation, filling and finishing and commercialisation of the vaccine in India and “low- and middle-income countries”, though the exact countries were not specified in the announcement of the partnership.

Early promise from Novavax's vaccine candidate for COVID-19

New Phase 1/2 on Novavax’s COVID-19 vaccine candidate NVX‑CoV2373 has shown that the therapy generated “robust antibody responses” when used with or without the company’s Matrix‑M adjuvant.

The study examined 131 healthy participants aged 18-59 years old. Antibody activity produced by the vaccine was observed as “numerically superior” to that seen in human convalescent sera, with all trial participants developing anti-spike IgG antibodies following initial dosing.

Novavax cuts works force by a third in struggle to restructure

Novavax released the news that it would cut away 30% of its workforce alongside third quarter results that revenues were halves. This drop in revenue resulted in a quarterly loss of $66.3 million.

The restructuring will incur a $3 million to $4 million expense, with job losses being effective immediately.  Alongside cutting away jobs, the company plans wider cost-cutting that will see cut backs on research and development, pre-commercialisation activities, capital equipment investments, project specific and general expenses.

Novavax rides high on crest of RSV vaccine wave

Novavax

The vaccine development company Novavax has announced positive top-line data from a mid-stage clinical trial of its candidate vaccine against respiratory syncytial virus (RSV) in older adults.

The company says RSV F-protein recombinant nanoparticle vaccine candidate, (RSV F Vaccine), was well tolerated and met the trial’s primary, secondary and exploratory objectives.

Novavax makes manufacturing promotions

Published on: 16/06/10

US biotech company Novavax has made a brace of manufacturing management promotions.

It has appointed John Madsen as head of process and manufacturing operations and Steven Pincus as head of analytical and quality operations.

Both will report to Novavax chief executive Rahul Singhvi, who said: "John and Steve are uniquely well-qualified to manage our manufacturing process development, and quality organisations.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches